三氧化二砷联合沙利度胺治疗骨髓增生异常综合征

Combination of arsenic trioxide and thalidomide therapy in myelodysplastic syndromes

目的:探讨沙利度胺联合三氧化二砷治疗骨髓增生异常综合征的有效性和安全性。方法:42例骨髓增生异常综合征患者分为2组,治疗组使用沙利度胺和三氧化二砷,对照组接受促红细胞生成素及输血为主的对症支持治疗。比较2组的疗效,观察药物的不良反应。结果:治疗组20例完全缓解1例,部分缓解3例,血液学改善11例,总有效率75%,未发现严重不良反应;对照组22例无完全缓解,部分缓解1例,血液学改善8例,总有效率40.91%,与治疗组比较,差异有统计学意义(P<0.05)。结论:沙利度胺联合三氧化二砷治疗骨髓增生异常综合征有效率高,不良反应轻微,耐受性好。

Objective：To observe the therapeutic effects and side-effects of combination of arsenic trioxide with thalidomide regimen for the treatment of myelodysp1astic syndromes（MDS）.Method：A total of 42 patients with MDS were enrolled.Twenty patients were treated with arsenic trioxide combined with thalidomide,and the other 22 patients only received supportive care.Result：The total response rate was 75% in the treated group,but 40.91% in the control group.Significant differences were found between the two groups（P0.05）.No severe side-effects were observed.Conclusion：Combination of arsenic trioxide with thalidomide regimen may be a choice for patients with MDS.The regimen is well tolerated.